230 related articles for article (PubMed ID: 30723666)
1. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.
Aoyama J; Hayashi H; Yajima C; Takoi H; Tanaka T; Kashiwada T; Kokuho N; Terasaki Y; Nishikawa A; Gono T; Kuwana M; Saito Y; Abe S; Seike M; Gemma A
Respir Med Case Rep; 2019; 26():193-196. PubMed ID: 30723666
[TBL] [Abstract][Full Text] [Related]
2. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
[TBL] [Abstract][Full Text] [Related]
3. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease：A case report.
Kagawa H; Tsujino K; Yamamoto Y; Iwai A; Hara R; Matsuki T; Fukushima K; Oshitani Y; Yoshimura K; Miki M; Miki K; Kitada S; Mori M; Kida H
Respir Med Case Rep; 2020; 29():101016. PubMed ID: 32055439
[TBL] [Abstract][Full Text] [Related]
4. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
6. Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Isono T; Nakajima H; Takano K; Kobayashi Y; Kawabata Y; Shimizu Y; Takayanagi N
Respir Med Case Rep; 2021; 34():101491. PubMed ID: 34381685
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
8. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
[TBL] [Abstract][Full Text] [Related]
9. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
10. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.
Yoshifuji H
Clin Med Insights Circ Respir Pulm Med; 2015; 9(Suppl 1):141-6. PubMed ID: 27081322
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
13. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
14. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Treatment of Anti-MDA5-Positive Amyopathic Dermatomyositis Accompanied by a Rapidly Progressive Interstitial Lung Diseases With Methylprednisolone Pulse Therapy Combined With Cyclosporine A and Hydroxychloroquine.
Zhang QC; Liu MY; Chen ZX; Chen YT; Lin CS; Xu Q
Front Med (Lausanne); 2020; 7():610554. PubMed ID: 33330573
[No Abstract] [Full Text] [Related]
16. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis.
Hamada-Ode K; Taniguchi Y; Kimata T; Kawaguchi Y; Shimamura Y; Kuwana M; Fujimoto S; Terada Y
Eur J Rheumatol; 2015 Jun; 2(2):83-85. PubMed ID: 27708934
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease.
Kaenmuang P; Navasakulpong A
Respirol Case Rep; 2021 Jan; 9(1):e00701. PubMed ID: 33343905
[TBL] [Abstract][Full Text] [Related]
18. Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies.
Hiramatsu T; Murano M; Nakai S; Murakami Y; Nishimoto K; Matsushima S; Harada M; Uto T; Sato J; Imokawa S; Suda T
Respir Med Case Rep; 2022; 36():101606. PubMed ID: 35242519
[TBL] [Abstract][Full Text] [Related]
19. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
[TBL] [Abstract][Full Text] [Related]
20. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
